Leukemia
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax + Azacitidine) or Intensive (7+3) Therapy in Patients Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia (NCT05735184)
- Details
ClinicalTrials.gov ID:
NCT05735184
Diagnosis Type:
NA
USOR Number:
- Address
,
P: